Major R&D Pipeline: 3ADCs
Core Operating Profit
Increased by 9.6 Bn JPY (Increased by 6.6 Bn JPY excl. forex impact)
FY2020 Results
34.1
Revenue
Cost of Sales
SG&A Expenses
R&D Expenses
Forex Impact
FY2021 Results
43.7
27.1
Positive Factors
3.6
4.0
7.1
Negative Factors
Revenue
incl. forex impact of +6.6
Cost of Sales
+27.1
+2.8 (Profit decreased)
Daiichi-Sankyo
(Bn JPY)
Improvement in cost of sales ratio by change in product mix
2.8
SG&A Expenses
+7.1 (Profit decreased)
Increase in expenses related to Enhertu due to an increase in profit share of
gross profit with AstraZeneca
R&D Expenses
+4.0 (Profit decreased)
Increase in 3ADCS* R&D investments
Forex Impact
+3.6 (Profit decreased)
Cost of Sales
+0.1
SG&A Expenses
+2.3
R&D Expenses
+1.2
* 3ADCs: 1) Enhertu, Trastuzumab deruxtecan (T-DXd, DS-8201), 2) Datopotamab deruxtecan (Dato-DXd, DS-1062)
and 3) Patritumab deruxtecan (HER3-DXd, U3-1402)
6View entire presentation